A 28-year-old woman with a history of recurrent infections and poor wound healing presents with oral candidiasis and a chronic non-healing leg ulcer. Laboratory workup reveals elevated NADP⁺ levels and reduced NADPH. Genetic testing confirms chronic granulomatous disease (CGD) due to NADPH oxidase deficiency. What is the most appropriate immediate next step in management?

Explanation

## Pathophysiology Context **Key Point:** Chronic granulomatous disease (CGD) results from defective NADPH oxidase, impairing the respiratory burst and neutrophil killing of catalase-positive organisms. **High-Yield:** NADPH (from pentose phosphate pathway) is the electron donor for NADPH oxidase: $$\text{NADPH} + H^+ + O_2 \xrightarrow{\text{NADPH oxidase}} \text{NADP}^+ + \text{O}_2^{\bullet-} \text{ (superoxide)}$$ Without this, neutrophils cannot generate reactive oxygen species (ROS) → recurrent infections with catalase-positive organisms (S. aureus, Burkholderia, Serratia, Aspergillus). ## Management Strategy in CGD ```mermaid flowchart TD A[CGD Diagnosed]:::outcome --> B[Establish Preventive<br/>Infection Strategy]:::action B --> C[Prophylactic Antibiotics<br/>TMP-SMX]:::action B --> D[Prophylactic Antifungal<br/>Itraconazole]:::action C --> E[Reduce Infection Burden<br/>& Inflammatory Complications]:::outcome D --> E E --> F{Recurrent Infections<br/>Despite Prophylaxis?}:::decision F -->|Yes| G[Add Interferon-gamma<br/>Therapy]:::action F -->|No| H[Continue Prophylaxis<br/>& Monitor]:::action G --> I[Improved Neutrophil<br/>Function]:::outcome ``` ## Immediate Management: Prophylaxis **Key Point:** The cornerstone of CGD management is **infection prevention**, not curative therapy. | Intervention | Rationale | Timing | |---|---|---| | **TMP-SMX prophylaxis** | Prevents PCP and S. aureus infections | Start immediately | | **Itraconazole prophylaxis** | Prevents Aspergillus infections (major cause of mortality) | Start immediately | | **Interferon-gamma** | Enhances residual NADPH oxidase activity; reserved for breakthrough infections | Add if infections recur | | **HSCT** | Only curative option; reserved for severe phenotype or failed prophylaxis | Elective, after stabilization | **Clinical Pearl:** Interferon-gamma (IFN-γ) is NOT first-line. It is added if prophylactic antibiotics and antifungals fail to prevent recurrent infections. It works by upregulating alternative pathways for ROS generation and improving neutrophil priming. **High-Yield:** CGD organisms to remember: - **Catalase-positive:** S. aureus, Burkholderia cepacia, Serratia, Nocardia, Aspergillus - **Why catalase-positive?** They destroy H₂O₂ (which neutrophils produce via other pathways), so they escape killing ## Why Prophylaxis First? 1. Reduces infection frequency and severity 2. Prevents chronic inflammatory complications (granulomas, abscesses) 3. Buys time for patient education and monitoring 4. HSCT is elective and reserved for severe/refractory cases 5. IFN-γ is added only if prophylaxis fails